Accelrys Announces Second Quarter Fiscal Year 2010 Financial Results

http://www.businesswire.com/news/home/20091105006300/en

SAN DIEGO--(Business Wire)--
Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for the quarter
ended September 30, 2009.

"Year-over-year increases in operating income, cash and deferred revenue
demonstrate another solid financial quarter for our business," said Max
Carnecchia, President and Chief Executive Officer of Accelrys. "From an
operating standpoint, we are also pleased with our performance. We recently had
a successful European User Group meeting and continued to innovate on the
product front with the announced release of our Materials Studio 5.0 software
suite. We also further validated our value to science-based companies outside
the pharmaceutical industry by entering into an agreement to implement a
large-scale agri-business solution built on our scientific business intelligence
platform."

Second Quarter 2010 Financial Results:

* Revenue for the quarter ended September 30, 2009 decreased 1% to $20.0 million
from $20.1 million for the same quarter of the previous year.
* Non-GAAP net income was $3.3 million, or $0.12 per diluted share, for the
current quarter compared to non-GAAP net income of $2.7 million, or $0.10 per
diluted share, for the same quarter of the previous year.
* GAAP net income was $1.8 million, or $0.07 per diluted share, for the current
quarter compared to GAAP net income of $1.2 million, or $0.04 per diluted share,
for the same quarter of the previous year.

Fiscal 2010 Year to Date Financial Results:

* Revenue for the six months ended September 30, 2009 decreased 1% to $40.1
million from $40.4 million for the same period of the previous year.
* Non-GAAP net income was $5.1 million, or $0.18 per diluted share, for the six
months ended September 30, 2009 compared to non-GAAP net income of $4.9 million,
or $0.18 per diluted share, for the same period of the previous year.
* GAAP net income was $2.6 million, or $0.09 per diluted share, for the six
months ended September 30, 2009 compared to GAAP net income of $1.3 million, or
$0.05 per diluted share, for the same period of the previous year.

Recent Business and Financial Highlights:

* Announced the release of Materials Studio 5.0 software suite, a
state-of-the-art modeling and simulation platform that transforms the efficiency
and effectiveness of chemical and materials research. The new release includes a
host of integrated product enhancements that deliver performance and usability
improvements that increase research productivity and reduce time-to-innovation
for industries including specialty chemicals, pharmaceuticals, consumer packaged
goods, heavy manufacturing, and electronics. These new product capabilities are
currently being used by Procter and Gamble, PQ Corporation, Taiyo Uden, and the
Army Research Laboratory, USA.
* Held our 2009 European User Group meeting in Barcelona, Spain, with strong
attendance from customers across the globe, as well as speakers from the leading
pharmaceutical and manufacturing companies, including AstraZeneca, Schering
Plough, Pfizer, Unilever and Sanofi-Aventis.

Non-GAAP Financial Measures:

This press release describes financial measures for operating income, net
income, and net income per diluted share that exclude stock-based compensation
expense, purchased intangible assets amortization and restructuring charges
(recoveries). These financial measures are not calculated in accordance with
generally accepted accounting principles (GAAP) and are not based on any
comprehensive set of accounting rules or principles.

Management believes these non-GAAP financial measures provide a useful measure
of the Company`s operating results, a meaningful comparison with historical
results and with the results of other companies, and insight into the Company`s
ongoing operating performance. Further, management and the Board of Directors
utilize these measures, in addition to GAAP measures, when evaluating and
comparing the Company`s operating performance against internal financial
forecasts and budgets. These non-GAAP financial measures should not be
considered as a substitute for, or superior to, measures of financial
performance prepared in accordance with GAAP. In addition, these non-GAAP
financial measures may be different from non-GAAP financial measures used by
other companies.

For additional information on the items excluded by the Company from its
non-GAAP financial measures please refer to the Form 8-K regarding this release
that was furnished today to the Securities and Exchange Commission.

The following table contains a reconciliation of the non-GAAP financial measures
to the most directly comparable GAAP financial measures (unaudited, amounts in
thousands, including footnotes):

Three Months Ended Six Months Ended
September 30, September 30,
2009 2008 2009 2008

GAAP Operating income $ 1,846 $ 1,278 $ 2,924 $ 1,420
Stock-based compensation expense1 1,021 1,114 1,809 1,993
Purchased intangible asset amortization2 381 381 762 762
Restructuring charges (recoveries)3 17 8 (74 ) 850
Non-GAAP Operating income $ 3,265 $ 2,781 $ 5,421 $ 5,025

GAAP Net income $ 1,846 $ 1,227 $ 2,590 $ 1,313
Stock-based compensation expense 1,021 1,114 1,809 1,993
Purchased intangible asset amortization 381 381 762 762
Restructuring charges (recoveries)3 17 8 (74 ) 850
Non-GAAP Net income $ 3,265 $ 2,730 $ 5,087 $ 4,918

GAAP Diluted net income per share $ 0.07 $ 0.04 $ 0.09 $ 0.05
Stock-based compensation expense 0.04 0.04 0.07 0.07
Purchased intangible asset amortization 0.01 0.01 0.03 0.03
Restructuring charges (recoveries)3 - - - 0.03
Non-GAAP Diluted net income per share4 $ 0.12 $ 0.10 $ 0.18 $ 0.18

1 Stock-based compensation expense is included in our condensed consolidated statements of operations as follows:

Three Months Ended Six Months Ended
September 30, September 30,
2009 2008 2009 2008
Cost of revenue $ 49 $ 106 $ 112 $ 204
Product development 229 253 451 476
Sales and marketing 292 312 458 468
General and administrative 451 443 788 845
Total stock-based compensation expense $ 1,021 $ 1,114 $ 1,809 $ 1,993

2 Purchased intangible asset amortization is included in the cost of revenue line in our condensed consolidated statements of operations.
3 Restructuring charges (recoveries) are included in the restructuring charges (recoveries) line in our condensed consolidated statements of operations.
4 Earnings per share amounts for the three months ended September 30, 2008 and the six months ended September 30, 2009 do not add due to rounding.

Conference Call Details:

At 5:00 p.m. ET, November 5, 2009, Accelrys will conduct a conference call to
discuss its financial results. To participate, please dial (866) 393-7459 (+
(706) 643-4624 outside the United States) and enter the access code, 37307429,
approximately 15 minutes before the scheduled start of the call. The conference
call will also be accessible live on the Investor Relations section of the
Accelrys website at www.accelrys.com.

A replay of the conference call will be available online at www.accelrys.com and
via telephone by dialing (800) 642-1687 (+1 (706) 645-9291 outside the United
States) and entering access code, 37307429, beginning 6:00 p.m. ET on November
5, 2009 through 11:59 p.m. ET on February 5, 2010.

About Accelrys:

Headquartered in San Diego, California, Accelrys develops scientific business
intelligence software and solutions for the life sciences, energy, chemicals,
aerospace, and consumer products industries. Our customers include many Fortune
500 companies and other commercial entities, as well as academic and government
entities. We have a vast portfolio of computer-aided design modeling and
simulation offerings which assist our customers in conducting scientific
experiments `in silico` in order to reduce the duration and cost of discovering
and developing new drugs and materials. Our scientific business intelligence
platform underlies most of our computer-aided design modeling and simulation
offerings. Our platform can be used with our products, our competitors` products
and our customers` proprietary predictive science products. Its flexibility,
ease-of-use and advanced chemical, text and image analysis and reporting
capabilities enable our customers to mine, aggregate, analyze and report
scientific data from disparate sources, thereby better utilizing scientific data
within their organizations. For more information about Accelrys, visit its
website at http://accelrys.com/.

Forward-Looking Statements:

Statements contained in this press release relating to the Company`s or
management`s intentions, hopes, beliefs, expectations or predictions of the
future are forward-looking statements. Such forward-looking statements
including, but not limited to, statements relating to the Company`s products and
prospects are subject to a number of risks and uncertainties. These include
risks that the Company will not achieve its anticipated results due to, among
other possibilities, an inability to withstand negative conditions in the global
economy or a lack of demand for or market acceptance of the Company`s products,
as well as the risks and uncertainties that are contained from time to time in
the Company`s filings with the U.S. Securities and Exchange Commission,
including, but not limited to, the Company`s Annual Report on Form 10-K for the
year ended March 31, 2009, quarterly reports on Form 10-Q and current reports on
Form 8-K. The Company`s actual results could differ materially from those
projected in such forward-looking statements due to these risks and
uncertainties, and the Company disclaims any intention or obligation to revise
any forward-looking statements whether as a result of new information, future
events or otherwise.

ACCELRYS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

Three Months Ended Six Months Ended
September 30, September 30,
2009 2008 2009 2008
Revenue $ 19,988 $ 20,112 $ 40,129 $ 40,412
Cost of revenue 3,350 3,545 6,800 7,005

Gross profit 16,638 16,567 33,329 33,407

Operating expenses:
Product development 3,551 3,832 7,454 8,110
Sales and marketing 7,812 8,190 15,955 16,307
General and administrative 3,412 3,259 7,070 6,720
Restructuring charges (recoveries) 17 8 (74 ) 850

Total operating expenses 14,792 15,289 30,405 31,987

Operating income 1,846 1,278 2,924 1,420
Interest and other income, net 273 350 268 623

Income before taxes 2,119 1,628 3,192 2,043
Income tax expense 273 401 602 730

Net income 1,846 1,227 2,590 1,313

Net income per share
Basic $ 0.07 $ 0.05 $ 0.09 $ 0.05

Diluted $ 0.07 $ 0.04 $ 0.09 $ 0.05

Weighted average shares used to compute basic and diluted net income per share
Basic 27,503 27,094 27,403 26,992
Diluted 27,901 27,367 27,662 27,177

ACCELRYS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

September 30, March 31,
2009 2009
Assets
Cash, cash equivalents, and marketable securities1 $ 79,983 $ 81,769
Trade receivables, net 8,577 21,860
Other assets, net2 55,919 56,985

Total assets $ 144,479 $ 160,614

Liabilities and stockholders` equity
Current liabilities, excluding deferred revenue 10,661 15,427
Total deferred revenue3 42,181 57,224
Noncurrent liabilities, excluding deferred revenue 7,256 7,204
Total stockholders` equity 84,381 80,759

Total liabilities and stockholders` equity $ 144,479 $ 160,614

1 Cash, cash equivalents, and marketable securities consist of the following
line items in our consolidated balance sheet: Cash and cash equivalents;
Marketable securities; Marketable securities, net of current portion; and
Restricted cash

2 Other assets, net, consists of the following line items in our consolidated
balance sheet: Prepaid expenses, deferred tax assets and other current assets;
Property and equipment, net; Goodwill; Purchased intangible assets, net; and
Other assets

3 Total deferred revenue consists of the following line items in our
consolidated balance sheet: Current portion of deferred revenue; and Deferred
revenue, net of current portion

Accelrys, Inc.
Rick Russo, 858-799-5200
or
Investor Relations
MKR Group
Charles Messman or Todd Kehrli, 323-468-2300
accl@mkr-group.com

Copyright Business Wire 2009